Bcr-Abl first generation drug Imatinib was proved to increase YAP suppression in chronic myeloid leukemia (CML) cells promoted by Verteporfin, involving PI3K-Akt and MAPK pathways as previously seen [47]. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.